Q4 2023 Innovate Corp Earnings Call

Participants

Anthony Rozmus; IR; Innovate Corp

Paul Voigt; CEO; Innovate Corp

Michael Sena; Chief Financial Officer; Innovate Corp

Presentation

Operator

Good afternoon, and welcome to innovate Corp's fourth quarter 2023 earnings conference call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Anthony Rasmus with Investor Relations. Please go ahead.

Anthony Rozmus

Good afternoon. Thank you for being with us to review innovate fourth quarter 2023 earnings results. We are joined today by Paul Boyd, innovate Interim CEO, and Mike can innovate, CFO. We have posted our earnings release and our slide presentation on our website at elevate corp.com. We will begin our call with prepared remarks to be followed by Q&A session.
This call is also being simulcast and will be archived on our website. During this call, management may make certain statements and assumptions which are not historical facts and will be forward-looking and are being made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward looking statements involve with assumptions and uncertainties and are subject to certain assumptions and risk factors that could cause these differences actual results to differ materially from these forward-looking statements.
Risk factors that could cause these differences are more fully discussed in the cautionary statement that is included in our earnings release, slide presentation and further detailed in our 10-K with the SEC.
In addition, the forward-looking statements included in this conference call are only made as of the date of this call, and as stated in our SEC reports, innovate disclaims any intent or obligation to update or revise these forward-looking statements, except as expressly required by law. Management will also refer to certain non-GAAP financial measures such as adjusted EBITDA.
We believe that these measures provide useful supplemental data that while not a substitute for GAAP measures, allow for greater transparency and a review of our financial and operational performance. At this point is my pleasure to turn things over to Paul Voigt.

Paul Voigt

Good afternoon. Innovate delivered revenues of $361 million and adjusted EBITDA of $21.5 million in the fourth quarter and revenues of $1.4 billion and adjusted EBITDA of $65 million for the full year of 2023. We are pleased with these results and the performance of our three operating segments in 2023. To provide some perspective of the magnitude of progress at innovate when we made the strategic decision to start the transformation of HC2 to innovate back in 2020.
At that time, annual revenue was $716.9 million, adjusted to exclude our former insurance company and adjusted EBITDA was only approximately $25.5 million. Since then, innovate has experienced significant growth, and today's results represent roughly a three year 25.7% CAGR on the top line and approximately 36.6% CAGR for the adjusted EBITDA.
Over that time, DBM has continued to be a cash flow machine for innovate and most recently expired strong margin expansion in 2023. Pansend has benefited from key milestones hit each year by MediBeacon, and R2 and Spectrum remains focused on delivering profitability by adding new station builds, launching new networks and existing exiting unprofitable operations.
We are pleased with the progress that innovate has made over the last three years, but there's still much work to be done. We will continue to look for ways to optimize the value in each of our assets and remain encouraged by the future effects at innovate.
Now moving on to the fourth quarter DBM Global delivered had another strong quarter with revenues of $353.8 million and adjusted EBITDA of $30 million. Year over year DBM, significantly expanding gross margins by approximately 200 basis points and adjust the EBITDA margin by 25 basis points to 16.4% and 8.5%, respectively.
As we forecasted at the beginning of 2023, DBM delivery to increase adjusted EBITDA margin for the full year 2023 of 7.2% compared to 6.4% for the full year 2022. DBM's total adjusted backlog, which takes into consideration awarded but not yet signed contracts, is beginning to stabilize and was at $1.2 billion at the end of the year.
Given the tremendous backlog DBM experienced in the past year, we would expect 2024 results for DBM to be slightly lower than 2023. That being said, we are optimistic that this will only be a short-lived phenomenon as opportunities at DBM. look strong exiting the year into 2025 and beyond when we expect to see more projects of size to enter the pipeline.
Moving on to Life Sciences R2 technologies had another incredible quarter on the heels of launching its new glacial FX system in Q3 2023 R2 sold out of glacial FX inventory in Q4, securing R2 best system sales growth in a single quarter. From Q3 to Q4, R2 experienced a 76% increase in North American system sales and in the full year 2023, experienced a 111% increase in North American system sales year over year.
This growth lent to R2 single largest revenue earnings quarter since inception, R2 continued its growth in other areas of the business, experiencing a 173% increase in monthly patient treated year over year at 106% increase in average monthly utilization per glacial provider from the same period last year.
The mix seen is being used post-operatively to reduce time and for skin conditions and greatly expanded the usefulness of the machine to date are to has provided over 20,000 patient treatments. R2 continues to expand global reach in fourth quarter with market approvals received in both Saudi Arabia and the UAE. Additionally, market awareness continues to skyrocket from 2022 to 2023. R2 experienced a 213% increase in social media impressions of 491% increase in provider locations searches, and a 50% increase in lead generation and product interest.
R2 glacial provider surveyed say that the customer satisfaction and practice retention rates have dramatically increased since the introduction of a glacial product, solidifying that the gLeaf chilled product portfolios, ability to improve patient outcomes through the reduction in inflammation is the new standard of care at MediBeacon. The Company continues to work through their substantive review for the kidney monitoring program with the FDA.
Medibeacon met with the FDA in the first quarter of 2024 and is working interactively to resolve outstanding questions in order to move to approval status, MediBeacon has disclosed positive findings in its pivotal study in 2023, for which it met the pre-negotiated primary and secondary endpoints for efficacy and safety, respectively. The study can be found at clinical studies that govern the study results are expected to post on this site within the next 30 days.
As a reminder, the FDA previously granted FDA breakthrough device designation in the United States. We continue to be pleased with the progress across the pants and portfolio. And at Spectrum, the company is gaining considerable traction with sizable new network launches. Specifically, we've launched free TV and three large Sports Net networks. These new network launches include favorable revenue agreements across the board and the ER early results are promising.
As a reminder, we are also focused on repurposing our spectrum to maximize revenues. We are entering into an agreement with the public broadcasters to provide a TSCE3 Dato stations to Lighthouse in networks signals. We are pursuing it public look for represent over 100 PBS stations in major markets across the country. In addition to light housing PBS signals, we will be pursuing PBS station commercial opportunities and dedicated casting and other profit applications.
As it relates to 5G broadcast TV, we are actively exploring opportunities in the United States and have filed an application with the SEC to convert existing stations to 5G broadcast in order to participate in Phase two proof of concept for most in important remind you here is that 5G technology will be able to readily deliver broadcast signals to hundreds of millions of smartphones across the United States using his existing technology. We are working closely with call com the technology leader in 5G broadcasting. This will allow broadcasting to optimize for future revenues.
Moving forward, we are highly focused on addressing our capital structure, which we believe is a key driver to the two underperformance of our stock price. Our focus for 2024 will be to utilize our non cash flowing assets to address our capital structure and set the company up for a refinance in 2024. To that end, we continue to make progress exploring opportunities for our non-cash flowing businesses.
However, exiting these businesses for the right value takes time, we are optimistic on the overall M&A market and hope to reach resolution in 2024 as we are beginning to see positive indicators in the market, along with positive momentum with these assets. As discussed above, we have engaged bankers as there has been incoming interest from strategics on both R2 and MediBeacon.
We announced in late February, we are launching a fully backstopped $35 million rights offering and a private sale to shore up our liquidity needs for 2024 and believe this will give us the runway we need to push our non cash flowing assets passed important milestones and exit these businesses for the right value.
As we move into 2024. Here, we are encouraged by the positioning of each of our business segments and look forward to updating you on their progress throughout the year.
With that, I'll turn it over to Mike for a review of our financials and capital structure.

Michael Sena

Thanks for. consolidated total revenue for the fourth quarter of 2023 was $361 million, a decrease of 11.8% compared to $409.3 million in the prior year period. The decrease was primarily driven by our Infrastructure segment and to a lesser extent, our Spectrum segment's. Net loss attributable to common stockholders for the fourth quarter of 2023 was $9.6 million, or $0.12 per share compared to a net loss of $7 million or $0.09 per share in the prior year.
Total adjusted EBITDA was $21.5 million in the fourth quarter of 2023, a decrease from $28.1 million in the prior year period. The decrease was driven by infrastructure life sciences, and spectrum segments by the elimination of equity method. Income from our investment management, which was sold in March of 2023, which was partially offset by our non-operated corporate center.
Our Infrastructure revenues decreased 10.9% to $353.8 million from $397.3 million in the prior year quarter. This decrease was primarily driven by the timing and size of projects of DBMG commercial steel fabrication and erection business, which was partially offset by an increase in revenue with the industrial maintenance and repair business bankers, steel and the construction construction modeling and detailed business due to timing and size projects.
Infrastructure adjusted EBITDA for the fourth quarter of 2022, a decrease to $30 million from $32.7 million in the prior year period. The decrease was primarily driven by an increase in recurring SG&A expenses and lower contributions from Banco steel, which was partially offset by increased margins of the industrial maintenance and repair business.
As of December 31, 2023 reported backlog was $1.1 billion on adjusted backlog, which takes into consideration awarded but not yet signed contracts was $1.2 billion compared to reported and adjusted backlog of $1.8 billion at the end of 2022.
As Paul explained earlier, we continue to see meaningful opportunities market and DBM remains focused on converting those opportunities on the backlog. BMG ended the quarter was $198.8 million in principal amount of debt, which is a decrease of $44.2 million from year end 2022, primarily driven by an early note repayment, normal debt ammortization payment, and the reduction of the credit facility. DBMG has been able to reduce its debt obligations through early payments and line reductions as invested working capital as those become to return to the business. A trend, we continue to see in early 2024. As backlog stabilizes, we expect flat working capital needs in 2024.
Additionally, on December 12, 2023, DBMG and EBM entered into an amendment that extended the maturity date of the revolving line from May 31, 2024. So August 15, 2025, increase to interest rate spread for the revolving line by [0.35%] and across all tiers and establish an interest rates for a 4.25%.
At Life Sciences, the increase in adjusted EBITDA losses for the quarter was primarily due to higher equity method losses recognized from pensions investment MediBeacon due to our additional investment into more of each of which resulted in previously suspended losses to be recognized during the investments carry them out being reduced to [zero]. This was partially offset by decrease in SG&A expenses at R2 driven by a decrease in marketing costs as a result of cost reduction initiatives and a decrease in compensation expenses.
At spectrum revenue was $5.7 million, a decrease of $5 million compared to the fourth quarter of 2022, primarily driven by the elimination of advertising revenues of US spectera, which [ceased] operations at the end of 2022. This was partially offset by an increase in Stage two and revenue, which launched new markets and networks with its customers during 2023.
Spectrum reported adjusted EBITDA in the fourth quarter decreased to $1.1 million from $2.5 million in the prior year quarter. The decrease was primarily due to a one-time benefit related to the termination and thus tuck in the prior-year period which was partially offset by decrease in [unrepeated] SG&A expenses in the prior period.
Non-operating corporate adjusted EBITDA losses were $2.5 million for the fourth quarter of 2023, an improvement from the fourth quarter of 2022 of $1.2 million. The improvement was primarily driven by the decrease in bonus expense and legal expenses. For the full year, adjusted EBITDA losses for 2023 were $13.5 million, an improvement from the full year 2022 of $3.2 million.
At the end of the fourth quarter, the company had $80.8 million of cash and cash equivalents, excluding restricted cash, compared to $80.4 million as of December 31, 2022. On a stand-alone basis as of December 31, our non-operating corporating segment, had cash and cash equivalents of $2.5 million compared to $9.1 million at the end of 2022.
As mentioned by Paul, we will launch in the a fully backstops rights offering and private sale to shore up liquidity. The proceeds will be used to settle an inter-company adventures for our February 1, 2024 interest payments and to help meet liquidity needs while we execute our strategy in 2024.
As of December 31, 2023, innovate at total principal outstanding indebtedness of $722.8 million, down $2.5 million from $725.3 million at the end of 2022, driven primarily by the decrease in infrastructures, outstanding debt, which was partially offset corporates, new unsecured note with CGIC and R2 additional borrowings from Lazard Capital.
With that, operator, we'd now like to open up the call for questions.

Question and Answer Session

Operator

Thank you. Ladies and gentlemen, we will now conduct the question and answer session. (Operator Instructions)
There are no further questions at this time. Paul. Please proceed with your closing remarks.

Paul Voigt

Yes, thank you. And I just want to say thank you, everybody, for your continued support, and we're working very hard and diligently to make this a very profitable company. Thank you very much.

Operator

Ladies and gentlemen, this concludes today's conference call. Thank you for joining. You may now disconnect.